Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hematopoietic niche drives FLT3-ITD acute myeloid leukemia resistance to quizartinib via STAT5-and hypoxia-dependent upregulation of AXL
Pierre‐Yves Dumas, Cécile Naudin, Severine Martin‐Lannerée, et al.
Haematologica (2019) Vol. 104, Iss. 10, pp. 2017-2027
Open Access | Times Cited: 71

Showing 26-50 of 71 citing articles:

Pathogenic and therapeutic roles of cytokines in acute myeloid leukemia
Omid Karimdadi Sariani, Sara Eghbalpour, Elahe Kazemi, et al.
Cytokine (2021) Vol. 142, pp. 155508-155508
Closed Access | Times Cited: 24
Overcoming Resistance: FLT3 Inhibitors Past, Present, Future and the Challenge of Cure
Debora Capelli, Diego Menotti, Alessandro Fiorentini, et al.
Cancers (2022) Vol. 14, Iss. 17, pp. 4315-4315
Open Access | Times Cited: 18
A Receptor Tyrosine Kinase Inhibitor Sensitivity Prediction Model Identifies AXL Dependency in Leukemia
Ahmad Nasimian, Lina Al Ashiri, Mehreen Ahmed, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3830-3830
Open Access | Times Cited: 10
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia
Chuhong Hu, Yvyin Zhang, Jie Yang, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 3
AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
Siyang Yan, Niels Vandewalle, Nathan De Beule, et al.
Cancers (2019) Vol. 11, Iss. 11, pp. 1727-1727
Open Access | Times Cited: 27
The Role of Hypoxic Bone Marrow Microenvironment in Acute Myeloid Leukemia and Future Therapeutic Opportunities
Samantha Bruno, Manuela Mancini, Sara De Santis, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 13, pp. 6857-6857
Open Access | Times Cited: 23
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
Shuai‐Shuai Ge, Songbai Liu, Shengli Xue
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia
Tonio Johannes Lukas Lang, Frédérik Damm, Lars Bullinger, et al.
Cancers (2023) Vol. 15, Iss. 18, pp. 4573-4573
Open Access | Times Cited: 8
TP-0903 is active in models of drug-resistant acute myeloid leukemia
Jae Yoon Jeon, Daelynn R. Buelow, Dominique A. Garrison, et al.
JCI Insight (2020) Vol. 5, Iss. 23
Open Access | Times Cited: 23
Establishment of tumor inflammasome clusters with distinct immunogenomic landscape aids immunotherapy
Qingyu Liang, Jianqi Wu, Xin Zhao, et al.
Theranostics (2021) Vol. 11, Iss. 20, pp. 9884-9903
Open Access | Times Cited: 18
Thymoquinone Inhibits Growth of Acute Myeloid Leukemia Cells through Reversal SHP-1 and SOCS-3 Hypermethylation: In Vitro and In Silico Evaluation
Futoon Abedrabbu Al-Rawashde, Muhammad Farid Johan, Wan Rohani Wan Taib, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 12, pp. 1287-1287
Open Access | Times Cited: 16
Key role of glutamine metabolism in persistence of leukemic cells upon exposition to FLT3 tyrosine kinase inhibitors
Raeeka Khamari, Claire Degand, Quentin Fovez, et al.
Experimental Hematology (2024) Vol. 137, pp. 104253-104253
Open Access | Times Cited: 2
Novel Approaches to Target Mutant FLT3 Leukaemia
Jörg P. Müller, Dirk Schmidt‐Arras
Cancers (2020) Vol. 12, Iss. 10, pp. 2806-2806
Open Access | Times Cited: 17
From Bench to Bedside and Beyond: Therapeutic Scenario in Acute Myeloid Leukemia
Carmelo Gurnari, Maria Teresa Voso, Jaroslaw P. Maciejewski, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 357-357
Open Access | Times Cited: 16
Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model
Mateusz Rytelewski, Karine G. Harutyunyan, Natalia Baran, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 16
Resistance to targeted therapies in acute myeloid leukemia
Rabea Mecklenbrauck, Michael Heuser
Clinical & Experimental Metastasis (2022) Vol. 40, Iss. 1, pp. 33-44
Open Access | Times Cited: 11
Gilteritinib for the treatment of relapsed and/or refractory FLT3-mutated acute myeloid leukemia
Christine M. McMahon, Alexander E. Perl
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 9, pp. 841-849
Closed Access | Times Cited: 16
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis
Anna Orlova, Heidi A. Neubauer, Richard Moriggl
Haematologica (2019) Vol. 104, Iss. 10, pp. 1907-1909
Open Access | Times Cited: 12
The AXL inhibitor bemcentinib overcomes microenvironment‐mediated resistance to pioglitazone in acute myeloid leukemia
Jaja Zhu, Hippolyte Guérineau, Anne‐Margaux Lefebvre‐Fortané, et al.
FEBS Journal (2024)
Open Access | Times Cited: 1
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies
Niels Vandewalle, Nathan De Beule, Ann De Becker, et al.
Experimental Hematology and Oncology (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 1
STAT5: From Pathogenesis Mechanism to Therapeutic Approach in Acute Leukemia
Mohammad Shahjahani, Amirreza Abroun, Najmaldin Saki, et al.
Laboratory Medicine (2019) Vol. 51, Iss. 4, pp. 345-351
Closed Access | Times Cited: 11
Dasatinib overcomes stroma-based resistance to the FLT3 inhibitor quizartinib using multiple mechanisms
Ami B. Patel, Anthony D. Pomicter, Dongqing Yan, et al.
Leukemia (2020) Vol. 34, Iss. 11, pp. 2981-2991
Open Access | Times Cited: 11
Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic Cells
Marine Dupont, Mathilde Huart, Claire Lauvinerie, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 453-453
Open Access | Times Cited: 7
BMX kinase mediates gilteritinib resistance inFLT3-mutated AML through microenvironmental factors
Daelynn R. Buelow, Bhavana Bhatnagar, Shelley Orwick, et al.
Blood Advances (2022) Vol. 6, Iss. 17, pp. 5049-5060
Open Access | Times Cited: 7
Rationale for a Combination Therapy with the STAT5 Inhibitor AC-4-130 and the MCL1 Inhibitor S63845 in the Treatment of FLT3-Mutated or TET2-Mutated Acute Myeloid Leukemia
Katja Seipel, Carolyn Graber, Laura Flückiger, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 15, pp. 8092-8092
Open Access | Times Cited: 9

Scroll to top